IDO1 and melanoma: The latest phase III trial ECHO-301 have reported that the combination of epacadostat (IDO1 selective inhibitor) and PD-1 inhibitor pembrolizumab did not provide any additional survival benefit compared to pembrolizumab alone in advanced melanoma patients (Long et al. 2019).